Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 05 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Simple noninvasive systems predict long-term outcomes in NAFLD

The latest issue of Gastroenterology investigates simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.

News image

Some patients with nonalcoholic fatty liver disease (NAFLD) develop liver-related complications, and have higher mortality than other patients with NAFLD.

Dr Paul Angulo and colleagues from Kentucky, USA determined the accuracy of simple, noninvasive scoring systems in identification of patients at increased risk for liver-related complications or death.

The research team performed a retrospective, international, multicenter cohort study of 320 patients diagnosed with NAFLD, based on liver biopsy analysis through 2002 and followed through 2011.

Patients were assigned to mild-, intermediate-, or high-risk groups based on cut-off values for 2 of the following; NAFLD fibrosis score, aspartate aminotransferase/platelet ratio index, FIB-4 score, and BARD score.

Outcomes included liver-related complications and death or liver transplantation.

14% of patients developed liver-related events
Gastroenterology

The researchers used multivariate Cox proportional hazard regression analysis to adjust for relevant variables and calculate adjusted hazard ratios.

During a median follow-up period of 105 months, 14% of patients developed liver-related events, and 13% died or underwent liver transplantation.

The adjusted hazard ratios for liver-related events in the intermediate-risk and high-risk groups, compared with the low-risk group, were 8, and 34, respectively.

Based on NAFLD fibrosis score, the adjusted hazard ratios for liver-related events in the intermediate-risk and high-risk groups were 8.8, and 21 based on the aspartate aminotransferase/platelet ratio index; and 6.2 and 6.6 based on the BARD score.

The adjusted hazard ratios for death or liver transplantation in the intermediate-risk and high-risk groups compared with the low-risk group were 4.2, and 9.8, respectively, based on the NAFLD fibrosis scores.

Based on aspartate aminotransferase/platelet ratio index and FIB-4 score, only the high-risk group had a greater risk of death or liver transplantation.

Dr Angulo's team concludes, "Simple noninvasive scoring systems help identify patients with NAFLD who are at increased risk for liver-related complications or death."

"NAFLD fibrosis score appears to be the best indicator of patients at risk."

"The results of this study require external validation."

Gastroenterology 2013: 145(4): 782-789
08 October 2013

Go to top of page Email this page Email this page to a colleague

 05 December 2016 
Reducing hospitalization in IBD
 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 29 November 2016 
Treating Zenker's diverticulum
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 23 November 2016 
Quality assurance standards for colonoscopy
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 21 November 2016 
Financial incentives and colorectal cancer screening
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Liver-related specialty care in patients with Hep C
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Physician perspectives on Hep C management
 15 November 2016 
Contraceptives and ulcerative colitis
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression
 10 November 2016 
Testosterone levels and cirrhosis outcomes in men
 10 November 2016 
Improving bowel quality before colonoscopy
 10 November 2016 
Fecal microbiota transplantation and CDI episodes
 09 November 2016 
Minimizing costs of esophagogastroduodenoscopy and colonoscopy
 09 November 2016 
Risk of TB in IBD patients receiving therapy
 09 November 2016 
Liver transplant wait-list and mortality in infants
 08 November 2016 
NSAIDS and risk of Barrett’s
 08 November 2016 
Ferritin levels and NAFLD mortality
 08 November 2016 
Alarms in the diagnosis of colorectal cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us